Literature DB >> 16640565

Receptor association and tyrosine phosphorylation of S6 kinases.

Heike Rebholz1, Ganna Panasyuk, Timothy Fenton, Ivan Nemazanyy, Taras Valovka, Marc Flajolet, Lars Ronnstrand, Len Stephens, Andrew West, Ivan T Gout.   

Abstract

Ribosomal protein S6 kinase (S6K) is activated by an array of mitogenic stimuli and is a key player in the regulation of cell growth. The activation process of S6 kinase involves a complex and sequential series of multiple Ser/Thr phosphorylations and is mainly mediated via phosphatidylinositol 3-kinase (PI3K)-3-phosphoinositide-dependent protein kinase-1 (PDK1) and mTor-dependent pathways. Upstream regulators of S6K, such as PDK1 and protein kinase B (PKB/Akt), are recruited to the membrane via their pleckstrin homology (PH) or protein-protein interaction domains. However, the mechanism of integration of S6K into a multi-enzyme complex around activated receptor tyrosine kinases is not clear. In the present study, we describe a specific interaction between S6K with receptor tyrosine kinases, such as platelet-derived growth factor receptor (PDGFR). The interaction with PDGFR is mediated via the kinase or the kinase extension domain of S6K. Complex formation is inducible by growth factors and leads to S6K tyrosine phosphorylation. Using PDGFR mutants, we have shown that the phosphorylation is exerted via a PDGFR-src pathway. Furthermore, src kinase phosphorylates and coimmunoprecipitates with S6K in vivo. Inhibitors towards tyrosine kinases, such as genistein and PP1, or src-specific SU6656, but not PI3K and mTor inhibitors, lead to a reduction in tyrosine phosphorylation of S6K. In addition, we mapped the sites of tyrosine phosphorylation in S6K1 and S6K2 to Y39 and Y45, respectively. Mutational and immunofluorescent analysis indicated that phosphorylation of S6Ks at these sites does not affect their activity or subcellular localization. Our data indicate that S6 kinase is recruited into a complex with RTKs and src and becomes phosphorylated on tyrosine/s in response to PDGF or serum.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16640565     DOI: 10.1111/j.1742-4658.2006.05219.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  9 in total

1.  Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells.

Authors:  Martina Vojtechová; Jolana Turecková; Dana Kucerová; Eva Sloncová; Jirí Vachtenheim; Zdena Tuhácková
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

2.  Macrophage infiltration into adipose tissue may promote angiogenesis for adipose tissue remodeling in obesity.

Authors:  Can Pang; Zhanguo Gao; Jun Yin; Jin Zhang; Weiping Jia; Jianping Ye
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-20       Impact factor: 4.310

3.  Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.

Authors:  Jennifer L Yori; Kristen L Lozada; Darcie D Seachrist; Jonathan D Mosley; Fadi W Abdul-Karim; Christine N Booth; Chris A Flask; Ruth A Keri
Journal:  Cancer Res       Date:  2014-07-14       Impact factor: 12.701

4.  Cluster analysis of protein array results via similarity of Gene Ontology annotation.

Authors:  Cheryl Wolting; C Jane McGlade; David Tritchler
Journal:  BMC Bioinformatics       Date:  2006-07-12       Impact factor: 3.169

5.  Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.

Authors:  Valentina Monica; Marco Lo Iacono; Enrico Bracco; Simone Busso; Laura Di Blasio; Luca Primo; Barbara Peracino; Mauro Papotti; Giorgio Scagliotti
Journal:  Oncotarget       Date:  2016-11-22

6.  Targeting mTOR and Src restricts hepatocellular carcinoma growth in a novel murine liver cancer model.

Authors:  Sarah Walker; Miriam Wankell; Vikki Ho; Rose White; Nikita Deo; Carol Devine; Brittany Dewdney; Prithi Bhathal; Olivier Govaere; Tania Roskams; Liang Qiao; Jacob George; Lionel Hebbard
Journal:  PLoS One       Date:  2019-02-22       Impact factor: 3.240

Review 7.  Beyond controlling cell size: functional analyses of S6K in tumorigenesis.

Authors:  Xueji Wu; Wei Xie; Wenxuan Xie; Wenyi Wei; Jianping Guo
Journal:  Cell Death Dis       Date:  2022-07-25       Impact factor: 9.685

8.  S6K2: The Neglected S6 Kinase Family Member.

Authors:  Olivier E Pardo; Michael J Seckl
Journal:  Front Oncol       Date:  2013-07-24       Impact factor: 6.244

9.  Adaptive metabolic rewiring to chronic SFK inhibition.

Authors:  Edgar Pinedo-Carpio; David Davidson; Veronica L Martinez Marignac; Justin Panasci; Raquel Aloyz
Journal:  Oncotarget       Date:  2016-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.